NASDAQ$ACRS
Aclaris Therapeutics Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Aclaris Therapeutics reported its financial results for the second quarter of 2024 and provided a corporate update.
Aclaris Therapeutics reported a net loss of $11.0 million and total revenue of $2.8 million for the second quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $149.9 million as of June 30, 2024.
- Initiated Phase 2a Study Activities for ATI-2138 in Atopic Dermatitis.
- Strengthened Balance Sheet Through Sale of Future OLUMIANT® Royalties for Proceeds of up to $31.5 Million.
- Net loss was $11.0 million for the second quarter of 2024 compared to $29.6 million for the second quarter of 2023.
- Total revenue was $2.8 million for the second quarter of 2024 compared to $1.9 million for the second quarter of 2023.
Headline financials
Revenue & EPS history
Aclaris Therapeutics · Revenue · Quarterly
$2.77M
Revenue by segment
Aclaris Therapeutics · $9.28M total across 2 segments · Q3 2023
- Licensing$8.58M-52.1%92.4%
- Contract research$705K-35.3%7.6%
Forward guidance
Aclaris anticipates that its cash, cash equivalents and marketable securities as of June 30, 2024 in combination with the $26.5 million from the sale of OLUMIANT® royalties and milestones will be sufficient to fund its operations into 2028, without giving effect to any potential new business development transactions, additional financing activities or the outcome of its strategic review.
Tailwinds
- Cash, cash equivalents and marketable securities will be sufficient to fund its operations into 2028.
- Sale of OLUMIANT® royalties and milestones contributed $26.5 million.
- Eligible to receive up to an additional $5.0 million upon the achievement of certain sales milestones.
- Focus remains on leveraging resources to maximize the potential of innovative drug candidates.
- Pursuing available opportunities and creating long-term value for patients and shareholders alike.
Headwinds
- Guidance does not give effect to any potential new business development transactions.
- Guidance does not give effect to additional financing activities.
- Guidance does not give effect to the outcome of its strategic review.
- Uncertainties inherent in the conduct of clinical trials.
- Aclaris’ reliance on third parties over which it may not always have full control.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-0.2%
Avg return
Earnings day
-1.6%
Avg return
5 days after
-0.7%
Avg return
30 days after
38%
16 / 42 earnings
Positive
+22.7%
Q4 2018
Best reaction
-15.3%
Q1 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.7% | +1.9% | -8.8% | |
| Q4 2025 | -5.2% | -8.2% | +6.3% | |
| Q3 2025 | -4.7% | -9.7% | +23.7% | |
| Q1 2025 | -0.8% | -3.8% | +9.9% | |
| Q4 2024 | -7.1% | -8.1% | -24.3% | |
| Q3 2024 | +10.4% | +18.5% | +77.5% | |
| Q2 2024 | -4.1% | -6.6% | -4.1% | |
| Q1 2024 | -6.9% | -10.7% | -21.4% | |
| Q4 2023 | -1.7% | +2.5% | +2.5% | |
| Q3 2023 | +0.9% | -11.5% | -81.0% | |
| Q2 2023 | -12.1% | -16.5% | -23.4% | |
| Q1 2023 | -7.8% | -12.1% | +4.5% | |
| Q4 2022 | -4.9% | -1.8% | -36.9% | |
| Q3 2022 | +4.3% | +9.3% | -0.2% | |
| Q2 2022 | +18.1% | +26.8% | +20.6% | |
| Q1 2022 | -8.9% | -4.5% | +35.3% | |
| Q4 2021 | +14.3% | +11.3% | +33.5% | |
| Q3 2021 | -12.4% | -11.0% | -31.4% | |
| Q2 2021 | +4.1% | +1.4% | +21.2% | |
| Q1 2021 | -2.2% | -8.6% | -8.8% | |
| Q4 2020 | +7.8% | +12.5% | +11.4% | |
| Q3 2020 | +7.0% | +7.5% | +0.8% | |
| Q2 2020 | +11.3% | +12.8% | +9.7% | |
| Q1 2020 | +12.7% | +10.3% | +13.5% | |
| Q4 2019 | -14.0% | -20.3% | -18.2% | |
| Q3 2019 | +20.4% | +11.7% | +2.5% | |
| Q2 2019 | -11.8% | -18.8% | -1.0% | |
| Q1 2019 | -11.2% | -14.7% | -29.0% | |
| Q4 2018 | +22.7% | +8.7% | -7.8% | |
| Q3 2018 | -1.8% | -13.2% | -29.8% | |
| Q2 2018 | -4.6% | -3.9% | -11.9% | |
| Q1 2018 | -0.5% | +4.2% | +1.4% | |
| Q4 2017 | -6.7% | -12.5% | -18.4% | |
| Q3 2017 | -5.7% | -3.2% | -7.9% | |
| Q2 2017 | -0.1% | -7.1% | +1.4% | |
| Q1 2017 | +6.3% | +5.8% | +0.6% | |
| Q4 2016 | -4.9% | -5.2% | +5.8% | |
| Q3 2016 | -1.0% | -2.7% | +39.7% | |
| Q2 2016 | +3.1% | +7.0% | +15.0% | |
| Q1 2016 | -15.3% | — | — | |
| Q4 2015 | -3.9% | — | — | |
| Q3 2015 | +5.8% | — | — | |
| Q2 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro